Blog
Updates on the strain of influenza vaccine recommended by WHO (2025-2026 northern hemisphere)
Mar
I. Updates regarding strains of influenza vaccines in the northern hemisphere of the northern hemisphere
To keep the vaccine effectivenessWhich regularly updates strains of influenza vaccines based on global epidemiological, virological and serological analyzes. February 28, 2025, which announced the recommended strains for the flu season in the 2025-2026 hemisphere1:
1
- A/Victoria/4897/2022 (H1N1) Virus similar to PDM09
- A/Croatta/10136RV/2023 (H3N2) -Wirus similar to each other
- AB/Austria/1359417/2021 (b/victoria lineage) virus
2. Three -wheeled protein or recombinant vaccines
- A/Wisconsin/67/2022 (H1N1) Virus similar to PDM09
- A/District of Columbia/27/2023 (H3N2) -Wirus similar to each other
- AB/Austria/1359417/2021 (b/victoria lineage) virus
3
- AB/Phuket/3073/2013 (lineage b/yamagata)
II. Comparison of vaccine ingredients 2024-2025 vs. 2025-2026
Table 1. Key updates for the composition of flu vaccine for the flu season in the northern hemisphere 2025–2026. Source: Sino Biological Inc.
| Vaccine type | Strains 2024-2025 | 2025-2026 updated strains | Key changes |
|---|---|---|---|
| Tri -valent eggs | A/Thailand/8/2022 (H3N2) | A/Craotia/10136RV/2023 (H3N2) | H3N2 Replacement of deformation |
| Cellular/recombinant triple | A/Massachusetts/18/2022 (H3N2) | A/District of Columbia/27/2023 (H.3N2) | H3N2 Replacement of deformation |
| Four | Tri-Valent + B/Phuket/3073/2013* | Tri-Valent + B/Phuket/3073/2013* | B/yamagata lineage stopped* |
1. H.3N2 Replacement of the strain
- Egg -based vaccines: Szczep 2022 (A/Thailand/8/2022) replaced by A/Croatia/10136RV/2023 (H. H3N2).
- Cellular/recombinant vaccines: Szczep 2022 (A/Massachusetts/18/2022) replaced by A/District of Columbia/27/2023 (H.3N2f).
2. No changes in the H1N1 or B/Victoria line
- H1N1 strains (eggs: A/Victoria/4897/2022; cell/recombinated: A/Wisconsin/67/2022) and B/Victoria Lineage (B/Austria/1359417/2021) remain unchanged.
3. Summary
- Core change: updated H3N2 The strains reflect their high level mutation indicator.
- Continuous development: subsequent adaptations to H3N2 Emphasize the need for quick adaptation of the virus evolution.
III. Recombinated antigens: Critical materials for vaccine testing
Table 2. Key target antigens (ha, e.g., e.g.) play an important role in the development of influenza, drug and diagnostic vaccine. Source: Sino Biological Inc.
| Protein | Function | Application |
|---|---|---|
| Ha (hemaglutinin) | It is associated with the receptors of the host cell, mediates in the viral input. | Development of vaccine, neutralizing antibody tests, diagnostics reagents. |
| That (neuraminidase) | Split siainic acid receptors for release of viral particles. | Development of antiviral drugs, vaccine optimization, diagnostic sets. |
| E.g. (nucleoprotein) | Binds a viral RNA, confirms the replication and stability of the genome. | Antiviral tests with a wide spectrum, diagnostic product development. |
Applications of recombinant antigens:
- Development of vaccine: used in testing the force of action, analysis of the level of antibodies based on ELISA and quality control.
- Acceleration of research: Replace traditional viral breeding methods, shortening research and development schedules.
IV. Sino Biological refers to comprehensive test reagents from influenza for vaccine strains 2025-2026
Sino Biological, a leading supplier of reagents and biological services, announced the edition of the latest portfolio of influenza research reagents. New offers, designed to support the development of vaccines during the northern hemisphere flu season 2025-2026, new offers include high-quality recombinant ha, na and e.g. These reagents are now available for immediate PRDD, providing researchers tools needed to accelerate the tests and contribute to global influenza prevention efforts.
References:
- World (2025). Recommendations announced in the composition of flu vaccine for the flu season in the northern hemisphere in the northern hemisphere 2025–2026. (online) who. Available at: https://www.who.int/news/item/28-02-2025-recommendations-announced-for-influenza-vaccine-composition-form.
- Andersen, TK ,. (2021). Pandemic preparation against flu: DNA vaccine for a quick relief. Immunology limits12. https://doi.org/10.3389/fimmu 201.747032.
